Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$6.4B

Aug7Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing its costs.

N/A

Revenue

Revenue figures are essential to assess the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer. Operating in the health care sector, it aims to address significant unmet medical needs in oncology, making its advancements crucial for patients and the broader health care landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing the estimate of -$0.58. The stock reacted positively, gaining 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are cautious as CG Oncology has missed earnings estimates in recent quarters. Investors are looking for signs of improvement in both EPS and revenue.

Bull Case

If CG Oncology can show a significant reduction in losses and an increase in revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and missed estimates could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This number will be crucial in determining if the company is making progress towards profitability or if losses are continuing.

How much revenue growth can CG Oncology report this quarter?

Revenue growth is a key indicator of demand for its products and overall business health, impacting investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CG Oncology's potential for recovery, as recent R&D advancements could lead to better-than-expected results.

Supporting Evidence

Options are pricing in a 36.98% move, indicating high uncertainty that could lead to a larger reaction than expected.

The company has shown resilience in past quarters, often reacting positively despite misses.

Recent trends in the biotech sector suggest a rebound in investor interest, which could favor CG Oncology.

Key Risk

If the EPS comes in below -$0.50, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether the company can show improvement in its financial performance after several disappointing quarters.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.75 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, suggesting high uncertainty around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.1% on the day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential decline of around 0.79%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any changes in R&D spending that could signal a shift in strategy.
3Management's outlook on market conditions and competition.
4Details on partnerships or collaborations that could enhance growth.
5Insights into patient feedback or clinical trial results.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

BP p.l.c.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing its costs.

N/A

Revenue

Revenue figures are essential to assess the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing the estimate of -$0.58. The stock reacted positively, gaining 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are cautious as CG Oncology has missed earnings estimates in recent quarters. Investors are looking for signs of improvement in both EPS and revenue.

Bull Case

If CG Oncology can show a significant reduction in losses and an increase in revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and missed estimates could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This number will be crucial in determining if the company is making progress towards profitability or if losses are continuing.

How much revenue growth can CG Oncology report this quarter?

Revenue growth is a key indicator of demand for its products and overall business health, impacting investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CG Oncology's potential for recovery, as recent R&D advancements could lead to better-than-expected results.

Supporting Evidence

Options are pricing in a 36.98% move, indicating high uncertainty that could lead to a larger reaction than expected.

The company has shown resilience in past quarters, often reacting positively despite misses.

Recent trends in the biotech sector suggest a rebound in investor interest, which could favor CG Oncology.

Key Risk

If the EPS comes in below -$0.50, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether the company can show improvement in its financial performance after several disappointing quarters.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.75 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, suggesting high uncertainty around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.1% on the day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses expectations, history suggests a potential decline of around 0.79%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any changes in R&D spending that could signal a shift in strategy.
3Management's outlook on market conditions and competition.
4Details on partnerships or collaborations that could enhance growth.
5Insights into patient feedback or clinical trial results.